Table 3.
Lipid, Lipoprotein, and Inflammation Markers in Postmenopausal Volunteers
| Plac + Plac | Plac + P | E2 + Plac | E2 + P | Treatment P Value | |
|---|---|---|---|---|---|
| Adiponectin, ng/mL | 13,400 ± 1190 | 10,530 ± 1170 | 12,520 ± 1400 | 10,270 ± 770 | 0.089 |
| Leptin, ng/mL | 31.7 ± 8.2 | 36.4 ± 9.5 | 35.2 ± 6.7 | 44.9 ± 8.8 | 0.30 |
| TGs, mg/dL | 154 ± 19 | 148 ± 14 | 126 ± 12 | 129 ± 20 | 0.53 |
| TC, mg/dL | 199 ± 9 | 192 ± 8 | 180 ± 7 | 164 ± 7.9 | 0.02 |
| HDL-C, mg/dL | 56 ± 4 | 50 ± 3.7 | 62 ± 5 | 47 ± 4 | 0.06 |
| LDL-C, mg/dL | 112 ± 8 | 112 ± 8 | 92 ± 7 | 91 ± 8 | 0.08 |
| NonHDL-C, mg/dL | 143 ± 10 | 142 ± 8 | 117 ± 7 | 116 ± 8 | 0.04 |
| Apo B, mg/dL | 0.90 ± 0.05 | 0.93 ± 0.05 | 0.77 ± 0.05 | 0.80 ± 0.07 | 0.13 |
| Lp(a), mg/dL | 17.7 ± 7.6 | 22.3 ± 5.5 | 29.5 ± 8.5 | 19.3 ± 8.3 | 0.60 |
| hsCRP, mg/dL | 0.16 ± 0.08 | 0.079 ± 0.024 | 0.186 ± 0.036 | 0.333 ± 0.114 | 0.018a |
| IL-6, pg/mL | 3.7 ± 0.9 | 2.9 ± 0.6 | 4.5 ± 1.0 | 5.4 ± 1.2 | 0.46 |
Data are mean ± SEM. In the analysis of covariance, age and visceral mass were covariates.TC, HDL-C, LDL-C, and nonHDL-C were lower in women receiving E2 treatment than in those without E2 replacement (post hocP = 0.006, P = 0.01, P = 0.012, and P = 0.004, respectively). The addition of P to E2 decreased HDL-C concentration (P = 0.019). Adiponectin levels were lower during P treatment (P = 0.019).
Abbreviation: Plac, placebo.
a
Because of nonnormality of hsCRP data, the Kruskal-Wallis test was used with post hoc contrasts. The hsCRP concentration in women treated with E2 and P was higher than in placebo-treated women (P = 0.018).